A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis

American Journal of Pathology

Volumn 167, Issue 2, 2005, Pages 545-554

  East, Emma ^a   Baker, David ^a   Pryce, Gareth ^a   Lijnen, H Roger ^b   Cuzner, M Louise ^a   Gverić, Djordje ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; FIBRIN; FIBRINOGEN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROFILAMENT PROTEIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL ADHESION; CELL MIGRATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DEMYELINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; MONONUCLEAR CELL; MOUSE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROFILAMENT; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASE; FEMALE; GENETICS; MALE; METABOLISM; MOUSE MUTANT; NERVE FIBER; PATHOLOGY; PHYSIOLOGY;

ANIMALS; AXONS; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FIBRIN; FIBRINOLYSIS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPLE SCLEROSIS; NERVE DEGENERATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 25144499286     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62996-3     Document Type: Article

References (57)

1. Lo EH, Wang X, Cuzner ML: Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res 2002, 69:1-9
2. Teesalu T, Hinkkanen AE, Vaheri A: Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am J Pathol 2001, 159:2227-2237
3. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, Newcombe J: The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996, 55:1194-1204
4. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, Rudge P, McDonald WI: Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenic and clinical implications. Brain 1990, 113:1477-1489
5. Wakefield AJ, More LJ, Difford J, McLaughlin JE: Immunohistochemical study of vascular injury in acute multiple sclerosis. J Clin Pathol 1994, 47:129-133
6. Seeds NW, Friedman G, Hayden S, Thewke D, Haffke S, McGuire P, Krystosek A: Plasminogen activators and their interaction with the extracellular matrix in neural development, plasticity and regeneration. Semin Neurosci 1996, 8:405-412
7. Gveric D, Hanemaaijer R, Newcombe J, van Lent NA, Sier CF, Cuzner ML: Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 2001, 124:1978-1988
8. Gveric D: Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 2003, 126:1590-1598
9. Akassoglou K, Kombrinck KW, Degen JL, Strickland S: Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J Cell Biol 2000, 149:1157-1166
10. Inoue A, Koh CS, Shimada K, Yanagisawa N, Yoshimura K: Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats. J Neuroimmunol 1996, 71:131-137
11. Paterson PY: Experimental allergic encephalomyelitis: a role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed Proc 1976, 35:2428-2435
12. Garcia-Monco JC, Coleman JP, Benach JP: Soluble urokinase receptor (uPAR.CD87) is present in serum and cerebrospinal fluid in patients with neurological diseases. J Neuroimmunol 2002, 129:216-223
13. Chapman HA: Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997, 9:714-724
14. Tarui T, Mazar AP, Cines DB, Takada Y: Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 2001, 276:3983-3990
15. Balabanov R, Lisak D, Beaumont T, Lisak RP, Dore-Duffy P: Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1). Clin Diag Lab Immunol 2001, 8:1196-1203
16. Washington RA, Becher B, Balabanov R, Antel J, Dore-Duffy P: Expression of the activation marker urokinase plasminogen activator receptor in cultured human central nervous system microglia. J Neurosci Res 1996, 45:392-399
17. Beschorner R, Schluesener HJ, Nguyen TD, Magdolen V, Luther T, Pedel I, Mattern R, Meyermann R, Schwab JM: Lesion-associated accumulation of uPAR/CD87-expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans. Neuropathol Appl Neurobiol 2000, 26:522-527
18. Dewerchin M, Van Nuffelen A, Wallays G, Bouché A, Moons L, Carmeliet P: Generation and characterisation of urokinase receptor-deficient mice. J Clin Invest 1996, 97:870-878
19. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368:419-424
20. Carmeliet P, Bouché A, De Clercq C, Janssen S, Pollefeyt S, Wyns S, Mulligan RC, Collen D: Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci 1995, 17:367-381
21. Bernard CC, Johns TG, Slavin AJ, Ichikawa M, Ewing C, Liu J, Bettadapura J: Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 1997, 75:77-88
22. Okuda Y, Okuda M, Bernard CC: Gender does not influence the susceptibility of C57BL/6 mice to develop chronic experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein. Immunol Lett 2002, 81:25-29
23. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H: Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984, 312:548-551
24. O'Neill JK, Baker D, Davison AN, Allen SJ, Butter C, Waldmann H, Turk JL: Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. J Neuroimmunol 1993, 45:1-14
25. Gveric D, Cuzner ML, Newcombe J: Insulin-like growth factors and binding proteins in multiple sclerosis plaques. Neuropathol Appl Neurobiol 1999, 25:215-225
26. Urano T, Takada Y, Ihara H, Takada A: Re-examination of the extent of the activation of Lys(78) plasminogen by tissue plasminogen activator in the presence of polymerised fibrin. Haemostasis 1996, 26:220-227
27. Declerck PJ, Verstreken M, Collen D: Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995, 74:1305-1309
28. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D: Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126:2191-2202
29. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285
30. Claudio L, Raine CS, Brosnan CF: Evidence of persistent blood-brain barrier abnormalities in chronic progressive multiple sclerosis. Acta Neuropathol 1995, 30:228-238
31. Akenami FO, Siren V, Koskiniemi M, Siimes MA, Teravainen H, Vaheri A: Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. J Clin Pathol 1996, 49:577-580
32. Akenami FO, Koskiniemi M, Farkkila M, Vaheri A: Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease. J Clin Pathol 1997, 50:157-160
33. Akenami FO, Siren V, Wessman M, Koskiniemi M, Vaheri A: Tissue plasminogen activator gene expression in multiple sclerosis brain tissue. J Neurol Sci 1999, 165:71-76
34. Ahmed Z, Gveric D, Pryce G, Baker D, Leonard JP, Cuzner ML, Diemel LT: Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol 2001, 158:2127-2138
35. Lu W, Bhasin M, Tsirka SE: Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis. J Neurosci 2002, 22:10781-10789
36. Akassoglou K, Strickland S: Nervous system pathology: the fibrin perspective. Biol Chem 2002, 383:37-45
37. Flick MJ, Du X, Witte DP, Jiroušková M, Soloviev DA, Busuttil SJ, Plow EF, Degen J: Leukocyte engagement of fibrin(ogen) via the integrin receptor aMb2/Mac-1 is critical for host inflammatory response in vitro. J Clin Invest 2004, 113:1596-1606
38. Languino LR, Duperray A, Joganic KJ, Fornaro M, Thornton GB, Altieri DC: Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intracellular adhesion molecule 1-fibrinogen recognition. Proc Natl Acad Sci USA 1995, 92:1505-1509
39. Perez RL, Ritzenhaler JD, Roman J: Transcriptional regulation of the interleukin-1b promoter via fibrinogen engagement of the CD18 intergin receptor. Am J Respir Cell Mol Biol 1999, 20:1059-1066
40. Smiley ST, King JA, Hancock WW: Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001, 167:2887-2894
41. Akassoglou K, Adams RA, Bauer J, Mercado P, Tseveleki V, Lassmann H, Probert L, Strickland S: Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumour necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci USA 2004, 101:6698-6703
42. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454
43. Kasza A, Kowanetz M, Poslednik K, Witek B, Kordula T, Koj A: Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of the plasminogen activator system in U373-MG astrocytoma cells. Cytokine 2001, 16:187-190
44. Blasi F, Carmeliet P: uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3:932-943
45. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT: Urokinase receptor (CD87) regulates leukocyte recruitment via b2 integrins in vivo. J Exp Med 1998, 188:1029-1037
46. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ: Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Psuedomonas aeruginosa infection. J Immunol 2000, 165:1513-1519
47. Gyetko MR, Sud S, Sonstein J, Polak T, Sud A, Curtis JL: Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA. J Immunol 2001, 167:5539-5542
48. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van der Poll T: Urokinase receptor is necessary for adequate host defense against Pneumococcal pneumonia. J Immunol 2002, 168:3507-3511
49. Sellebjerg F, Sørensen TL: Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull 2003, 61:347-355
50. Irigoyen JP, Mun̄oz-Cánoves P, Montero L, Koziczak M, Nagamine Y: The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999, 56:104-132
51. Longstaff C, Merton RE, Fabregas P, Felez J: Characterization of cell-associated plasminogen activation catalyzed by urokine-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87). Hemost Thromb Vasc Biol 1999, 93:3839-3846
52. Chen Z, Strickland S: Neuronal death in the hippocampus is promoted by plasmin catalysed degradation of laminin. Cell 1997, 91:917-925
53. Gold LI, Rostagno A, Frangione B, Passalaris T: Localization of the cleavage sites on fibronectin following digestion by urokinase. J Cell Biol 1992, 50:441-452
54. Carmeliet P, Moons L, Lijnen HR, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D: Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997, 17:439-444
55. Cuzner ML, Opdenakker G: Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 1999, 94:1-14
56. Bjartmar C, Wujek JR, Trapp BD: Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003, 206:165-171
57. Neumann H: Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. Curr Opin Neurol 2003, 16:267-273